Sagar Lonial, MD, FACP, on Why This MRD Approach Is 'Premature' in MM

By Chadi Nabhan, MD, MBA, FACP - Last Updated: August 1, 2023

Blood Cancers Today Editor-in-Chief Sagar Lonial, MD, FACP, discusses how he approaches frontline therapy for multiple myeloma (MM), why he thinks certain approaches to minimal residual disease (MRD) in MM are “premature,” and the data that show why sustained MRD negativity is key, with host Chadi Nabhan, MD, MBA, FACP.

Catch up on earlier episodes of The HemOnc Pulse here.

Advertisement
Advertisement
Advertisement
Editorial Board